{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-086678","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2022-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.152029+00:00","generated_at":"2026-06-26T16:05:20.310428+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acumen reports FY2021 net loss $100.6M; Phase 1 ACU193 topline results expected H1 2023","bullets":["Cash, cash equivalents and marketable securities $225.9M at Dec 31, 2021; provides runway through 2025.","Net loss $100.6M for FY2021 includes $81.2M non-cash fair value adjustment; operating loss $19.6M.","R&D expenses $12.3M (up from $8.0M) driven by clinical trial initiation; G&A $7.3M (up from $1.4M).","Topline results from INTERCEPT-AD Phase 1 trial of ACU193 now expected first half of 2023 due to slower enrollment from COVID-19.","Kim Drapkin appointed to Board of Directors effective Apr 1, 2022; three new team members added in Q4 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-086678","json":"https://secwatch.observer/filing/0001193125-22-086678.json","markdown":"https://secwatch.observer/filing/0001193125-22-086678.md","text":"https://secwatch.observer/filing/0001193125-22-086678.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000119312522086678/0001193125-22-086678-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000119312522086678/d302531d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T16:05:20.310428+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}